Medicenna Therapeutics Corp (MDNA) - Total Assets
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) holds total assets worth CA$13.06 Million CAD (≈ $9.45 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medicenna Therapeutics Corp - Total Assets Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's total assets have evolved over time, based on quarterly financial data. Also see MDNA market cap overview for the company's overall valuation and market capitalisation.
Medicenna Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (March 2025)
Medicenna Therapeutics Corp's total assets of CA$13.06 Million consist of 99.3% current assets and 0.7% non-current assets. Review Medicenna Therapeutics Corp (MDNA) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$24.84 Million | 87.5% |
| Accounts Receivable | CA$2.69 Million | 9.5% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$159.00K | 0.6% |
| Intangible Assets | CA$52.00K | 0.2% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MDNA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medicenna Therapeutics Corp's current assets represent 99.3% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 87.5% of total assets in 2025, up from 0.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 87.5% of total assets.
Medicenna Therapeutics Corp Competitors by Total Assets
Key competitors of Medicenna Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Medicenna Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 10.09 | 10.26 |
| Quick Ratio | 2.68 | 10.09 | 10.26 |
| Cash Ratio | 2.20 | 9.45 | 0.00 |
| Working Capital | CA$8.09 Million | CA$28.84 Million | CA$38.04 Million |
Medicenna Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Medicenna Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.46 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 48.3% |
| Total Assets | CA$28.38 Million |
| Market Capitalization | $25.65 Million USD |
Valuation Analysis
Near Book Valuation: The market values Medicenna Therapeutics Corp's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Medicenna Therapeutics Corp's assets grew by 48.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual total assets of Medicenna Therapeutics Corp from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | CA$28.38 Million ≈ $20.53 Million |
+48.33% |
| 2024-03-31 | CA$19.13 Million ≈ $13.84 Million |
-47.50% |
| 2023-03-31 | CA$36.45 Million ≈ $26.36 Million |
+55.38% |
| 2022-03-31 | CA$23.46 Million ≈ $16.97 Million |
-44.49% |
| 2021-03-31 | CA$42.25 Million ≈ $30.56 Million |
+11.20% |
| 2020-03-31 | CA$38.00 Million ≈ $27.49 Million |
+632.47% |
| 2019-03-31 | CA$5.19 Million ≈ $3.75 Million |
+18.58% |
| 2018-03-31 | CA$4.37 Million ≈ $3.16 Million |
-69.80% |
| 2017-03-31 | CA$14.48 Million ≈ $10.48 Million |
+151.66% |
| 2016-03-31 | CA$5.76 Million ≈ $4.16 Million |
+2011.45% |
| 2015-03-31 | CA$272.56K ≈ $197.17K |
-51.57% |
| 2014-03-31 | CA$562.85K ≈ $407.15K |
-- |
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more